Livedo racemosa in lymphocytic vasculitis.
Toh C, Choi ECE, Tan CL.
QJM. 2022 Dec 12;115(12):866-867. doi: 10.1093/qjmed/hcac198.
Cutaneous vasculitis in autoinflammatory diseases.
Chen KR.
J Dermatol. 2024 Feb;51(2):150-159. doi: 10.1111/1346-8138.17030. Epub 2023 Nov 13.
Raynaud's phenomenon.
Herrick AL, Wigley FM.
Best Pract Res Clin Rheumatol. 2020 Feb;34(1):101474. doi: 10.1016/j.berh.2019.101474. Epub 2020 Jan 29.
A Review of Raynaud's Disease.
Temprano KK.
Mo Med. 2016 Mar-Apr;113(2):123-6.
Raynaud's phenomenon-an update on diagnosis, classification and management.
Pauling JD, Hughes M, Pope JE.
Clin Rheumatol. 2019 Dec;38(12):3317-3330. doi: 10.1007/s10067-019-04745-5. Epub 2019 Aug 16.
Amantadine-Induced Livedo Racemosa.
Criado PR, Alavi A, Valente NY, Sotto MN.
Int J Low Extrem Wounds. 2016 Mar;15(1):78-81. doi: 10.1177/1534734615603566. Epub 2015 Sep 3.
Treatment for Livedoid Vasculopathy: A Systematic Review.
Micieli R, Alavi A.
JAMA Dermatol. 2018 Feb 1;154(2):193-202. doi: 10.1001/jamadermatol.2017.4374.
ESVM guidelines - the diagnosis and management of Raynaud's phenomenon.
Belch J, Carlizza A, Carpentier PH, Constans J, Khan F, Wautrecht JC, Visona A, Heiss C, Brodeman M, Pécsvárady Z, Roztocil K, Colgan MP, Vasic D, Gottsäter A, Amann-Vesti B, Chraim A, Poredoš P, Olinic DM, Madaric J, Nikol S, Herrick AL, Sprynger M, Klein-Weigel P, Hafner F, Staub D, Zeman Z.
Vasa. 2017 Oct;46(6):413-423. doi: 10.1024/0301-1526/a000661. Epub 2017 Sep 12.
Livedoid Vasculopathy.
Majmundar VD, Syed HA, Baxi K.
2024 Mar 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
Vasculitis in antiphospholipid syndrome.
Lally L, Sammaritano LR.
Rheum Dis Clin North Am. 2015;41(1):109-23, ix. doi: 10.1016/j.rdc.2014.09.009.
